loading page

Early complete response of primary bone marrow B-cell lymphoma treated with Rituximab-based CHOP therapy, assessed by flow cytometry and IGH rearrangement
  • +3
  • Yoshimi Nabe,
  • Shohei Kikuchi,
  • Yusuke Kamihara,
  • Akinori Wada,
  • Jun Muarakami,
  • Tsutomu Sato
Yoshimi Nabe
Toyama Daigaku Fuzoku Byoin
Author Profile
Shohei Kikuchi
Toyama Daigaku Fuzoku Byoin
Author Profile
Yusuke Kamihara
Toyama Daigaku Fuzoku Byoin
Author Profile
Akinori Wada
Toyama Daigaku Fuzoku Byoin
Author Profile
Jun Muarakami
Toyama Daigaku Fuzoku Byoin
Author Profile
Tsutomu Sato
Toyama Daigaku Fuzoku Byoin
Author Profile

Abstract

Primary bone marrow B-cell lymphoma (PBML) is a special subtype of DLBCL which can be repeatedly sampled and evaluated by FCM and IGH rearrangement. Evaluation of early response by FCM and IGH assessments in the midpoint of treatment could be valuable for predicting treatment outcome.

Peer review status:IN REVISION

14 May 2021Submitted to Clinical Case Reports
15 May 2021Assigned to Editor
15 May 2021Submission Checks Completed
27 May 2021Reviewer(s) Assigned
06 Jun 2021Review(s) Completed, Editorial Evaluation Pending
06 Jun 2021Editorial Decision: Revise Minor